HRAS and neoplasm: The basal tumor cluster #3 demonstrated transcriptional downregulation of HRAS (Fig. 3g, right panel); cell dormancy (Fig. 3h); and a higher expression of IGFBP7, MDK, and B2M (Fig. 3i), recapitulating those of the tipifarnib-resistant (or cluster B) BC159-T#3 PDX tumor cells.